Clinical and microbiological characteristics of bacterial infections in patients with cirrhosis. A prospective cohort study from Argentina and Uruguay

• DOI: 10.1016/j.aohep.2023.101097
• Publication Date: 2023-04-06T06:34:29Z
• Authors: Carolina Vazquez; María Nelly Gutie...; Sabrina Barbero; Lorena del Carmen...; Marina Agozino; José Luis Fernandez; María Margarita A...; Nadia Lorena Grigera; Florencia Antinucci; Orlando Nicolas F...; María Dolores Murga; María Daniela Perez; Ana Gracia Palazzo; Liria Martinez Re...; Ivonne Giselle Du...; Julio Daniel Voro...; Victoria Trevizan; Sofía Bulaty; Fernando Bessone; Marcelo Valverde; Martín Elizondo; Silvia Mabel Borzi; Teodoro Eduardo S...; Adriano Carlos Ma...; Sebastian Eduardo...; Diego Arufe; Ezequiel Demirdjian; María Pia Raffa; Mirta Peralta; Hugo Alberto Fain...; Cintia Elizabet V...; Pablo Marcelo Ruiz; José Emanuel Mart...; Leandro Alfredo H...; Andrea Odzak; Melisa Dirchwolf; Astrid Smud; Manuel Mendizabal; Pablo Anibal Calz...; Ana Martinez; Jesica Tomatis; Andres Bruno; Agñel Ramos; Josefina Pages; Silvina Tevez; Adrian Carlos Gadano; Diego Hernan Giunta; Sebastián Marciano
• Keywords: Cefepime

there is insufficient data regarding bacterial infections in patients with cirrhosis to support recommendations for empiric antibiotic treatments, particularly Latin America. This study aimed evaluate infection's clinical impact and microbiological characteristics, intending serve as a platform revise current practices.multicenter prospective cohort of from Argentina Uruguay. Patient infection-related information were collected, focusing on microbiology, susceptibility patterns, outcomes.472 included. Spontaneous urinary tract (UTIs) registered 187 (39.6%) 116 (24.6%) patients, respectively, representing the most common infections. Of 256 culture-positive infections, 103 (40.2%) caused by multidrug-resistant organisms (reaching 50% UTI), 181 (70.7%) received adequate initial treatment. The coverage cefepime ceftriaxone was over 70% empirical treatment community-acquired spontaneous but ceftazidime´s only 40%. For all UTI cases healthcare-associated or nosocomial lower-spectrum antibiotics that covered at least isolations imipenem meropenem. During hospitalization, second infection diagnosed 9.8% 23.9% required one organ support, 19.5% died.short-term mortality very high, high percentage organisms, UTIs. provided might adapt recommendations, related Clinical Trials (NCT03919032).